- Sharp has invested more than €20 million to expand injectable packaging, assembly and cold-chain storage capacity at its facilities in Belgium and the Netherlands.
- The expansion supports a range of injectable formats and forms part of a wider $100 million investment announced in November 2025.
Sharp has announced an investment of more than €20 million to expand capacity and capabilities at its European packaging facilities, responding to sustained demand in the injectables market. The programme focuses on assembly, labelling, packaging and cold storage for injectable formats, including autoinjectors, pen devices, pre-filled syringes and vials.
The investment targets Sharp’s sites in Hamont-Achel, Belgium, and Heerenveen, the Netherlands. In Belgium, the expansion will quadruple existing cold-chain warehouse capacity and double ambient storage space. The site will also add a new syringe assembly and blister packaging suite, alongside additional device assembly and packaging capacity. Collaborative robot technology has been introduced to improve production efficiency on adjacent pre-filled syringe and autoinjector lines.
The Hamont-Achel facility has also been upgraded with a carport solar system, which is expected to supply around 50% of the site’s electricity demand once fully commissioned in mid-2026. Sharp said the system aligns with its sustainability objectives while supporting increased operational demand.
In the Netherlands, Sharp will expand GMP production capacity at its Heerenveen facility, including the addition of two Grade D packaging suites. The upgrades will support new syringe assembly and packaging programmes, as well as vial packaging capacity, with operations due to come online in 2026. The company said the investment strengthens its ability to support pharmaceutical clients with injectable drug launches through its contract manufacturing and CDMO services in Europe.
“Our European facilities have a long-established reputation for successfully delivering the complex packaging services required for injectable drug formats.”
Robert O’Beirn, Managing Director, Sharp Clinical & Sharp Europe
